We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

AI Advancements Enable Leap into 3D Pathology

By LabMedica International staff writers
Posted on 10 May 2024
Print article
Image: Tripath (far right) outperforms current clinical baseline (far left) and 2D deep learning baselines (middle) in cancer recurrence risk prediction (Photo courtesy of Mass General Brigham)
Image: Tripath (far right) outperforms current clinical baseline (far left) and 2D deep learning baselines (middle) in cancer recurrence risk prediction (Photo courtesy of Mass General Brigham)

Human tissue is complex, intricate, and naturally three-dimensional. However, the thin two-dimensional tissue slices commonly used by pathologists to diagnose diseases provide only a limited view of the tissue's full complexity. As a result, there is a growing trend in pathology towards the examination of tissue in its three-dimensional form. Unfortunately, 3D pathology datasets can contain vastly more data than their 2D counterparts, rendering manual analysis impractical. Now, researchers have developed new, deep-learning models capable of utilizing 3D pathology datasets to predict clinical outcomes.

Tripath, developed by researchers from Mass General Brigham (Somerville, MA, USA) and their collaborators, aims to bridge the computational challenges of processing 3D tissue and predicting outcomes based on 3D morphological features. In their study, the team utilized two 3D high-resolution imaging techniques to capture images of curated prostate cancer specimens. These models were trained to assess the risk of prostate cancer recurrence using volumetric human tissue biopsies.

Tripath has demonstrated superior performance compared to traditional pathologists and has outperformed existing deep learning models that rely on 2D morphology and thin tissue slices, by comprehensively capturing 3D morphologies from the entire tissue volume. While further validation in larger datasets is necessary before this innovative approach can advance to clinical application, the research team remains optimistic about its potential to enhance clinical decision-making.

“Our approach underscores the importance of comprehensively analyzing the whole volume of a tissue sample for accurate patient risk prediction, which is the hallmark of the models we developed and only possible with the 3D pathology paradigm,” said lead author Andrew H. Song, PhD, of the Division of Computational Pathology in the Department of Pathology at Mass General Brigham.

Related Links:
Mass General Brigham

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.